MSTN and cancer: Genetic deletion strategies and soluble receptor/neutralizing antibodies have shown efficacy in attenuating musculoskeletal loss during cancer cachexia (18, 19) and spaceflight (20), and several GDF8-targeting pharmaceutical products are currently in clinical development (21–24).